Adverum Biotech
Karina N. is an experienced financial executive currently serving as Vice President and Controller at Adverum Biotechnologies, Inc. since August 2021. Prior to this role, Karina held multiple positions at Intarcia Therapeutics, Inc. from November 2015, including Executive Director and Corporate Controller, Vice President and Chief Accounting Officer, and Director of Accounting. Earlier career experience includes serving as Director of Financial Reporting at PaxVax, Inc. from July 2014 to November 2015, and an extensive tenure at Ernst & Young from November 2003 to July 2014, where Karina advanced to the position of Audit Senior Manager.
Adverum Biotech
10 followers
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.